At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Parallel Group, Single And Multiple Dose Study To Evaluate The Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function
In Brief
A Phase 4 clinical trial evaluating Maraviroc, Ritonavir, and 1 other intervention for Human Immunodeficiency Virus (HIV) Infection. Completed, enrolled 30 participants across 2 sites.
Detailed Summary
The purpose of this study is to assess whether a dosing adjustment is needed in patients with renal impairment.
Study Details
Timeline
Interventions
Maraviroc 300 mg (150 mg x 2 tablets) x single dose
Maraviroc 150 mg tablet twice daily x 7 days
Ritonavir 100 mg capsule twice daily x 7 days
Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
Maraviroc 150 mg tablet once daily x 7 days
Ritonavir 100 mg capsule twice daily x 7 days
Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
Maraviroc 150 mg tablet once every 48 hours x 7 days
Ritonavir 100 mg capsule twice daily x 7 days
Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
Maraviroc 300 mg (150 mg x 2 tablets) x single dose
Maraviroc 300 mg (150 mg x 2 tablets) x single dose one hour following completion of hemodialysis
Maraviroc 300 mg (150 mg x 2 tablets) x single dose three hours prior to start of hemodialysis